in5points
FinanceAsianet Newsable

SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

in5points

  1. SRPT stock dropped 4% after Citi reiterated a 'Sell' rating.

  2. Citi flagged potentially stronger competition in the Duchenne muscular dystrophy exon-skipping market.

  3. Citi expects increased rivalry in the DMD exon-skipping space.

3h ago · original ↗
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space · in5points